You just read:

ChemoCentryx Announces Phase II Clinical Trial of CCX140, a Novel, Orally-Available Small Molecule Antagonist of Chemokine Receptor CCR2

News provided by

ChemoCentryx, Inc.

Mar 22, 2010, 08:30 ET